A Phase 3 interventional study of Experimental Group A and C meningococcal polysaccharide vaccine and Control Group A and C meningococcal polysaccharide vaccine in Meningitis, Meningococcal, sponsored by Institute of Medical Biology, Chinese Academy of Medical Sciences. Completed at 1 site in China. Open to participants aged 2 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Institute of Medical Biology, Chinese Academy of Medical Sciences · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Meningitis, Meningococcal with a site in China — 5 open to participants now, 8 under way, 5 of them phase 3. Meningitis, Meningococcal · China.
Among the 19 studies in Meningitis, Meningococcal with a site in China, this one is the 2nd largest by enrollment, is one of 2 that started in 2020, is one of 10 in phase 3, and was the 5th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →5 of the 19 studies in Meningitis, Meningococcal with a site in China are open now. Recruiting first, the newest first:
Sinovac Biotech Co., Ltd · Sites in China
Ages 3 mo–5 mo · Healthy volunteers
Sinovac Biotech Co., Ltd · Sites in China
Ages 6 mo–11 mo · Healthy volunteers
Sinovac Biotech Co., Ltd · Sites in China
Ages 12 mo–23 mo · Healthy volunteers
CanSino Biologics Inc. · Sites in China
Ages 2 mo–6 yrs · Healthy volunteers
Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · Sites in China
Ages 3 mo–15 yrs · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 2 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 10 · Phase 4 2
First in 2015; this study’s year is marked. 2 started in 2020.
This study's enrollment of 1,280 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 840 across the 19 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 8 most frequent:
Institute of Medical Biology, Chinese Academy of Medical Sciences is the lead sponsor of 29 studies on the registry; 10 are open to participants now.
Institute of Medical Biology, Chinese Academy of Medical Sciences has 1 study filed under Meningitis, Meningococcal — fewer than ten, so there is no comparison to draw.
4 of the studies in Meningitis, Meningococcal with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07505888Phase 3Sinovac Biotech Co., LtdPhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years | 2026-11 |
| NCT07505836Phase 3Sinovac Biotech Co., LtdPhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months | 2027-01 |
| NCT07505823Phase 3Sinovac Biotech Co., LtdPhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months | 2027-04 |
| NCT07505810Phase 3Sinovac Biotech Co., LtdPhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Meningitis, Meningococcal with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, double-blinded, and controlled phase III clinical trial of the Group A and C meningococcal polysaccharide vaccine to evaluate the safety and immunogenicity of the vaccine in healthy infants aged 2-6 years.
This study was divided into two stages. The first stage study was an early safety assessment study among 80 subjects. The first stage study was conducted gradually in 20 subjects aged 18-50 years, 20 subjects aged 7-17 years, and 40 subjects aged 2-6 years. The second phase was a randomized, double-blind, controlled, non-inferiority phase III clinical trial in 1200 healthy infants aged 2-6 years, to evaluate the immunogenicity and safety of the experimantal vaccine after immunization.
18-50 years group:
Inclusion Criteria:
Exclusion Criteria:
7-17 years group:
Inclusion Criteria
Exclusion Criteria:
2-6 years group:
Inclusion Criteria
Exclusion Criteria:
The Second stage study (A phase III clinical trial )
Inclusion Criteria
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose of Experimental Group A and C meningococcal polysaccharide vaccine
Biological: Experimental Group A and C meningococcal polysaccharide vaccine
One dose of Control Group A and C meningococcal polysaccharide vaccine
Biological: Control Group A and C meningococcal polysaccharide vaccine
One dose of Experimental Group A and C meningococcal polysaccharide vaccine
One dose of Control Group A and C meningococcal polysaccharide vaccine
Seroconversion rate of Group A meningococcal bactericidal antibody
Seroconversion rate of Group A meningococcal bactericidal antibody at day 28 after vaccination
Time frame: 28 days after vaccination
Seroconversion rate of Group C meningococcal bactericidal antibody
Seroconversion rate of Group C meningococcal bactericidal antibody at day 28 after vaccination
Time frame: 28 days after vaccination
Adverse reactions/events rate
Occurence of adverse reactions/events after vaccination
Time frame: 7 days after vaccination
Adverse reactions/events rate
Occurence of adverse reactions/events after vaccination
Time frame: 28 days after vaccination
Serious adverse events
Occurence of Serious adverse events after vaccination
Time frame: 6 months after the second vaccination
GMT of Group A meningococcal bactericidal antibody
GMT of Group A meningococcal bactericidal antibody at day 28 after the second vaccination
Time frame: 28 days after the second vaccination
GMT of Group C meningococcal bactericidal antibody
GMT of Group C meningococcal bactericidal antibody at day 28 after the second vaccination
Time frame: 28 days after the second vaccination
GMT of IgG antibody against Hepatitis A
GMT of IgG antibody against Hepatitis A at day 28 after vaccination
Time frame: 28 days after the second vaccination
Seropositive rate of IgG antibody against Hepatitis A
Seropositive rate of IgG antibody against Hepatitis A at day 28 after vaccination
Time frame: 28 days after the second vaccination
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2020 to primary completion in Apr 2021, 7 months.
Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 7 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion May 2021 → Apr 2021 and completion Dec 2021 → Sep 2021.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Medical Biology, Chinese Academy of Medical Sciences